Drug susceptibility pattern of Mycobacterium tuberculosis isolates from patients of category-II failure of pulmonary tuberculosis under directly observed treatment short-course from North India

BioScience Trends

Volumn 6, Issue 3, 2012, Pages 110-114

  Prasad, Rajendra ^a   Verma, Sanjay Kumar ^b   Garg, Rajiv ^a   Jain, Amita ^a   Anand, Suneesh C ^a   Hosmane, Giridhar Belur ^c   Verma, Rajendra Kumar ^d   Kushwaha, Narendra Singh ^a   Kant, Surya ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b GSVM MEDICAL COLLEGE   (India)

^c NITTE DEEMED TO BE UNIVERSITY   (India)

^d Regency Hospital Limited   (India)

Author keywords

Category II; Failure; MDR; RNTCP; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; COHORT ANALYSIS; DIRECTLY OBSERVED THERAPY; DRUG EFFECT; HUMAN; INDIA; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; TREATMENT FAILURE;

ANTIBIOTICS, ANTITUBERCULAR; COHORT STUDIES; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; INDIA; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

BACILLI (CLASS); MYCOBACTERIUM TUBERCULOSIS;

EID: 84866781779     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2012.v6.3.110     Document Type: Article

References (21)

1. Global tuberculosis control - surveillance, planning, financing: WHO Report 2008. WHO/HTM/TB/2008.393.
2. Uplekar MW, Rangans S. Private doctors and tuberculosis control in India. Tuber Lung Dis. 1993; 74:332-337.
3. Prasad R, Nautiyal RG, Mukerji PK, Jain A, Singh K, Ahuja RC. Treatment of new pulmonary tuberculosis patients: What do allopathic doctors do in India? Int J Tuberc Lung Dis. 2002; 6:895-902.
4. International Union against Tuberculosis and Lung Diseases: Minimum Requirements, Role and Operation in a low income country. The Public Health Service National Tuberculosis Reference Laboratory and the National Laboratory network. 1998; 72-76.
5. WHO. Treatment of tuberculosis: Guidelines for national programmes. 2nd ed., WHO/TB/97.220. Geneva, Switzerland, WHO, 1997.
6. Salaniponi FM, Nyirenda TE, Kemp JR. Characteristics, management and outcome of patients with recurrent tuberculosis under routine programme conditions in Malawi. Int J Tuberc Lung Dis. 2003; 7:948-952.
7. Joseph P, Chandrasekaran V, Thomas A, Gopi PG, Rajeswari R, Balasubramanian R, Santha T. Influence of drug susceptibility on treatment outcome and susceptibility profile of 'failures' to Category-II regimen. Indian J Tuberc. 2006; 53:141-148.
8. Quy HTW, Lsn NTN, Borgdoff MW. Drug resistance among failure and relapse cases of tuberculosis: Is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis. 2003; 7:631-636.
9. Colles JG. Textbook of practical medical microbiology. Lowenstin Jenses Medium. p. 410.
10. Allen B, Baker RJ. In: Mycobacteria. Isolation, Identification and Sensitivity testing. Butterworth, London, 1968; p. 17.
11. Kubica GP. Differential identification of mycobacteria. VII. Key features for identification of clinically significant mycobacteria. Am Rev Resp Dis. 1973; 107:9-21.
12. Espinal MA, Kim SJ, Suarez PG. Standard short - Course chemotherapy for drug resistant tuberculosis. JAMA. 2000; 283:2537-2545.
13. Baghdadi JE, Remus N, Laaboudi L, Benslimane A. Chronic cases of tuberculosis in Casablanca, Morocco. Int J Tuberc Lung Dis. 2003; 7:660-664.
14. Kritski AL, Rodrigues de Jesus LS, Andrade MK, Werneck-Barroso E, Vieira MA, Hoffner A, Riley LW. Retreatment tuberculosis cases: Factors associated with drug resistance and adverse outcomes. Chest. 1997; 111:1162-1167.
15. Vijay S, Balasangameshwara VH, Jagannatha PS. Retreatment outcome of smear positive tuberculosis cases under DOTS in Bangalore City. Indian J Tuberc. 2002; 49:195-204.
16. D'souza DT, Mistry NF, Vira TS, Dholakia Y, Hoffner S, Pasvol G, Nicol M, Wilkinson RJ. High levels of multidrug resistant tuberculosis in new and treatmentfailure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health. 2009; 9:211.
17. Mahadev B, Kumar P, Agarwal SP, Chauhan LS, Srikantaramu N. Surveillance of drug resistance to antituberculosis drugs in districts of Hoogli in west Bengal and Mayurbhanj in Orissa. Indian J Tuberc. 2005; 52:5-10.
18. Santha T, Gopi PG, Rajeswari R, Selvakumar N, Subramani R, Chandrasekaran V, Rani B. Is it worth treating Category-I failure patients with Category-II regimen? Indian J Tuberc. 2005; 52:203-206.
19. Behra D, Balamugesh T. Profile of treatment failure in tuberculosis-experience from as tertiary care hospital. Lung India. 2006; 23:103-105.
20. Kimerling ME, Kluge H, Vezhnina N, Iacovazzi T, Demeulenaere T, Portaels F, Matthys F. Inadequacy of the current WHO retreatment regimen in the central Siberian prison: Treatment failure and MDR-TB. Int J Tuberc Lung Dis. 1999; 3:451-453.
21. Prasad R, Verma SK, Garg R. Failure of DOTS Category-II treatment: A report on 3 cases. J Assoc Physicians India. 2003; 51:423-424.